These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 9668390)

  • 41. Behavioral and biochemical expression of D1-receptor supersensitivity following SCH 23390 repeated administrations.
    Gandolfi O; Roncada P; Dall'Olio R; Montanaro N
    Brain Res; 1988 Jul; 455(2):390-3. PubMed ID: 2969768
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Withdrawal from continuous or intermittent cocaine administration: changes in D2 receptor function.
    King GR; Ellinwood EH; Silvia C; Joyner CM; Xue Z; Caron MG; Lee TH
    J Pharmacol Exp Ther; 1994 May; 269(2):743-9. PubMed ID: 8182540
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The effect of amantadine HCl on haloperidol-induced striatal dopamine neuron hypersensitivity.
    Allen RM; Flemenbaum A
    Biol Psychiatry; 1979 Jun; 14(3):541-4. PubMed ID: 573144
    [No Abstract]   [Full Text] [Related]  

  • 44. Antipsychotic-like profile of alstonine.
    Costa-Campos L; Lara DR; Nunes DS; Elisabetsky E
    Pharmacol Biochem Behav; 1998 May; 60(1):133-41. PubMed ID: 9610935
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Double dissociation of the effects of haloperidol and the dopamine D3 receptor antagonist ABT-127 on acquisition vs. expression of cocaine-conditioned activity in rats.
    Banasikowski TJ; Bespalov A; Drescher K; Behl B; Unger L; Haupt A; Schoemaker H; Sullivan JP; Gross G; Beninger RJ
    J Pharmacol Exp Ther; 2010 Nov; 335(2):506-15. PubMed ID: 20724485
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ganglioside GM1 counteracts the enhancing effects of subacute toluene exposure on apomorphine-induced locomotor activity.
    von Euler G; Ogren SO; Fuxe K; Gustafsson JA
    Toxicol Lett; 1992 Nov; 63(2):165-9. PubMed ID: 1455448
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Spontaneous activity and apomorphine stereotypy during and after withdrawal from 3 1/2 months continuous administration of haloperidol: some methodological issues.
    Waddington JL; Gamble SJ
    Psychopharmacology (Berl); 1980; 71(1):75-7. PubMed ID: 6779327
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mechanisms for metoclopramide-mediated sensitization and haloperidol-induced catalepsy in rats.
    Agovic MS; Yablonsky-Alter E; Lidsky TI; Banerjee SP
    Eur J Pharmacol; 2008 Jun; 587(1-3):181-6. PubMed ID: 18457824
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Behavioral sensitization following subchronic apomorphine treatment--possible neurochemical basis.
    Vaughn DM; Severson JA; Woodward JJ; Randall PK; Riffee WH; Leslie SW; Wilcox RE
    Brain Res; 1990 Aug; 526(1):37-44. PubMed ID: 2150341
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Influence of local administration of apomorphine on citrulline extracellular level in the striatum: participation of the dopamine D1 and D2 receptors].
    Savel'ev SA
    Ross Fiziol Zh Im I M Sechenova; 2005 Aug; 91(8):942-8. PubMed ID: 16252690
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Animal models of tardive dyskinesia: their use in the search for new treatment methods.
    Goetz CG; Klawans HL; Carvey P
    Mod Probl Pharmacopsychiatry; 1983; 21():5-20. PubMed ID: 6140633
    [No Abstract]   [Full Text] [Related]  

  • 52. Chronic electroconvulsive shock and chronic haloperidol administration are not additive in effects on dopamine receptors.
    Globus M; Lerer B; Hamburger R; Belmaker RH
    Neuropharmacology; 1981 Nov; 20(11):1125-8. PubMed ID: 7198723
    [No Abstract]   [Full Text] [Related]  

  • 53. Lack of potency of metoclopramide's metabolites in various dopaminergic models.
    Stanley M; Wazer D; Virgilio J; Kuhn CM; Benson DI; Meyerson LR
    Pharmacol Biochem Behav; 1983 Feb; 18(2):263-6. PubMed ID: 6682229
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of apomorphine on retention of a brightness discrimination in dopamine supersensitive rats.
    Honza R; Schumacher H; Klauck A; Grecksch G; Matthies H
    Behav Neural Biol; 1984 May; 41(1):23-9. PubMed ID: 6540561
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Haloperidol depresses the accumulation of apomorphine in the striatum of the rat.
    Vetulani J; Melzacka M; Wiszniowska G
    Eur J Pharmacol; 1978 May; 49(1):117-8. PubMed ID: 658123
    [No Abstract]   [Full Text] [Related]  

  • 56. Facilitation by alpha-adrenolytics of apomorphine gnawing behavior: depression of threshold apomorphine concentration in the striatum of the rat.
    Wiszniowska-Szafraniec G; Danek L; Reichenberg K; Vetulani J
    Pharmacol Biochem Behav; 1983 Jul; 19(1):19-21. PubMed ID: 6226051
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of intra-amygdalar dopamine agonists and antagonists on gastric stress lesions in rats.
    Ray A; Henke PG; Sullivan RM
    Neurosci Lett; 1988 Feb; 84(3):302-6. PubMed ID: 3352956
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Behavioral effects of apomorphine and diisobutyrylapomorphine in the mouse.
    Baldessarini RJ; Kula NS; Walton KG
    Psychopharmacology (Berl); 1977 Jun; 53(1):45-53. PubMed ID: 407613
    [No Abstract]   [Full Text] [Related]  

  • 59. The effect of lithium on chronic haloperidol enhanced apomorphine aggression in rats.
    Allikmets LH; Stanley M; Gershon S
    Life Sci; 1979 Jul; 25(2):165-70. PubMed ID: 573834
    [No Abstract]   [Full Text] [Related]  

  • 60. Cortical and striatal in vivo uptake and metabolism of plasma choline in the rat: effects of haloperidol and apomorphine.
    Aquilonius SM; Eckernäs SA
    Acta Pharmacol Toxicol (Copenh); 1976 Jul; 39(1):129-40. PubMed ID: 988965
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.